DeCure for Developmental and epileptic encephalopathy, 48
DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for developmental and epileptic encephalopathy, 48 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDevelopmental and epileptic encephalopathy, 48 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for developmental and epileptic encephalopathy, 48 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The term developmental and epileptic encephalopathy (DEE) describes a group of paediatric epilepsies where cognitive impairment results from both the underlying genetic or neurobiological cause and the direct effect of frequent seizures and interictal epileptiform activity. Many DEEs are linked to gene variants, and by August 2022 there were 105 genes associated with DEE according to OMIM. A 2023 study from a reference centre in Northeast Brazil examined the genetic profile of patients with DEE. Onset is typically in early childhood. The distinction from pure epileptic encephalopathy (EE) is clinically important: in EE, cognition is directly harmed by epileptic activity and can often revert to near normal baseline with aggressive treatment, whereas in developmental encephalopathy (DE) the epileptiform activity has minimal effect on function and aggressive antiseizure medication is unlikely to help. Patients with DEE sit between these categories and might benefit from a precision medicine approach to reduce the overall burden of epilepsy.
A 2006 case report describes a child whose epilepsy evolved from treatment-responsive focal epilepsy at 18 months to treatment-resistant focal epilepsy with an epileptic encephalopathy by age 3, illustrating poorly understood age-related changes in seizure susceptibility and drug responsiveness. A 2015 review notes that cognitive and developmental outcomes in epileptic encephalopathy are hypothesised to result from an interplay between the underlying epileptic pathology and the acquired consequences of repetitive seizures and discharges that straddle interictal and ictal boundaries, but it presents critical questions that remain unanswered about this relationship.
A 2025 review summarises currently well-established DEE syndromes and available precision therapies, emphasising the importance of recognising treatable or modifiable entities within this group. However, the review does not report concrete survival or response rates from any trial. A 2021 paper states that neurocognition in DEE is not improved by seizure control alone, though some precision therapies may help. No abstract provides data from a controlled trial showing that any specific drug improves developmental outcomes in DEE.
What is still missing are adequately powered randomised trials that separate the effect of seizure reduction from the effect of the underlying aetiology on development, validated biomarkers to stratify patients who will benefit from aggressive versus conservative treatment, and funding for precision medicine trials targeting the specific genetic subtypes now recognised.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Epileptic Disorders · 2021 · 126 citations · open access
Developmental and epileptic encephalopathies: recognition and approaches to care
AbstractThe term "developmental and epileptic encephalopathy" (DEE) refers to when cognitive functions are influenced by both seizure and interictal epileptiform activity and the neurobiological process behind the epilepsy. Many DEEs are related to gene variants and the onset is typically during early childhood. In this setting, neurocognition, whilst not improved by seizure control, may benefit from some precision therapies. In patients with non-progressive diseases with cognitive impairment and co-existing epilepsy, in whom the epileptiform activity does not affect or has minimal effect on function, the term "developmental encephalopathy" (DE) can be used. In contrast, for those patients with direct impact on cognition due to epileptic or epileptiform activity, the term "epileptic encephalopathy" (EE) is preferred, as most can revert to their normal or near normal baseline cognitive state with appropriate intervention. These children need aggressive treatment. Clinicians must tailor care towards individual needs and realistic expectations for each affected person; those with DE are unlikely to gain from aggressive antiseizure medication whilst those with EE will gain. Patients with DEE might benefit from a precision medicine approach in order to reduce the overall burden of epilepsy.
Epileptic encephalopathies: Optimizing seizure control and developmental outcome
AbstractCognitive and developmental outcomes in patients with epileptic encephalopathy are hypothesized to result from an interplay between the underlying epileptic pathologic substrate and the acquired consequences of frequent and repetitive seizures and epileptiform discharges that often straddle the interictal and ictal boundaries. This article briefly reviews the evidence related to this assumption, presents critical questions that need to be answered to clarify this relationship, and advances a set of concrete steps that may help improve developmental patient outcomes.
Frontiers in Pediatrics · 2025 · 2 citations · open access
Progress of ketogenic diet in the treatment of developmental epileptic encephalopathy
AbstractDevelopmental epileptic encephalopathy (DEE) is a severe neurological disorder caused by underlying genetic abnormalities and frequent epileptic activity. It is characterized by early-onset, drug-resistant epilepsy, abnormal electroencephalogram (EEG) findings, and developmental delay or regression. DEE is associated with high rates of disability and mortality. The ketogenic diet (KD) is a well-established non-pharmacological treatment for refractory epilepsy and has demonstrated therapeutic efficacy in several DEE subtypes. In certain cases, it may reduce or even eliminate the need for pharmacological interventions. This review discusses the current clinical application of KD in children with DEE and summarizes key factors influencing its therapeutic effectiveness.
International Journal of Epilepsy · 2025 · 1 citations · open access
Developmental and Epileptic Encephalopathies: Progress in Understanding and Clinical Implications
AbstractAbstract Developmental and epileptic encephalopathies (DEEs) are a group of complex pediatric epilepsies associated with adverse neurodevelopmental outcomes and multiaxial neurological morbidities. The understanding of DEE has evolved from its initial genetic underpinnings, to a clinically driven term encompassing a broader group of etiologies. Although individually rare, the DEEs constitute a sizeable group of pediatric epilepsies. It is especially important to recognize treatable or modifiable entities in this group. This review attempts to highlight the progress in understanding, along with the evolution of the conceptual framework of DEEs. A summary of the currently well-established DEE syndromes is provided along with available precision therapies, which might help the treating physician in the appropriate evaluation and management of the affected children.
A Child with Epilepsy: Initial Presentation and Subsequent Course
AbstractPresented is the case of a child with epilepsy with dramatic evolution between the ages of 18 months and 3 years. Initially, the case is one of treatment-responsive focal epilepsy, but then evolves to treatment-resistant focal epilepsy with an epileptic encephalopathy. The case demonstrates the poorly understood entities of age-related changes in seizure suspectibility, seizure types, and drug responsiveness.
Arquivos de Neuro-Psiquiatria · 2023 · 0 citations · open access
Genetic profile of patients with developmental and epileptic encephalopathy at a reference center in Northeast Brazil
AbstractBackground: The developmental and epileptic encephalopathy (DEE) diseases where there is developmental impairment related to both the underlying etiology independent of epileptiform activity and the epileptic encephalopathy. Many DEEs have a genetic basis that, by themselves, can alter the neurodevelopmental delay. By August 2022, there were 105 genes associated with DEE according to OMIM.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
